PL2928905T3 - Sposób oczyszczania białek terapeutycznych - Google Patents

Sposób oczyszczania białek terapeutycznych

Info

Publication number
PL2928905T3
PL2928905T3 PL13861334T PL13861334T PL2928905T3 PL 2928905 T3 PL2928905 T3 PL 2928905T3 PL 13861334 T PL13861334 T PL 13861334T PL 13861334 T PL13861334 T PL 13861334T PL 2928905 T3 PL2928905 T3 PL 2928905T3
Authority
PL
Poland
Prior art keywords
therapeutic proteins
clean
clean therapeutic
proteins
therapeutic
Prior art date
Application number
PL13861334T
Other languages
English (en)
Inventor
Hung Pham
Jeffrey Michael Hey
Darren Nguy
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL2928905T3 publication Critical patent/PL2928905T3/pl

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
PL13861334T 2012-12-05 2013-12-05 Sposób oczyszczania białek terapeutycznych PL2928905T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261733761P 2012-12-05 2012-12-05
EP13153898 2013-02-04
US13/803,740 US20140154233A1 (en) 2012-12-05 2013-03-14 Method of purifying therapeutic proteins
AU2013203357A AU2013203357B2 (en) 2012-12-05 2013-04-10 A method of purifying therapeutic proteins
EP13861334.4A EP2928905B1 (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins
PCT/AU2013/001414 WO2014085861A1 (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins

Publications (1)

Publication Number Publication Date
PL2928905T3 true PL2928905T3 (pl) 2019-05-31

Family

ID=47630209

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13861334T PL2928905T3 (pl) 2012-12-05 2013-12-05 Sposób oczyszczania białek terapeutycznych

Country Status (12)

Country Link
US (5) US20140154233A1 (pl)
EP (2) EP3483173A1 (pl)
JP (3) JP6411360B2 (pl)
KR (2) KR102403847B1 (pl)
CN (2) CN104981476B (pl)
AU (2) AU2013203357B2 (pl)
BR (1) BR112015012854B1 (pl)
CA (2) CA3185085A1 (pl)
PL (1) PL2928905T3 (pl)
RU (1) RU2685956C2 (pl)
SG (2) SG10201704484QA (pl)
WO (1) WO2014085861A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112972B2 (en) 2012-03-13 2018-10-30 Octapharma Ag Process for production of fibrinogen and fibrinogen produced thereby
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
AU2017205364B2 (en) * 2016-01-07 2021-03-04 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions
EP4293116A3 (fr) 2016-07-06 2024-01-24 Laboratoire Français du Fractionnement et des Biotechnologies Fibrinogène liquide stable
EP3506915B1 (en) 2016-09-01 2024-03-06 Plas-Free Ltd Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
BR112020002234A2 (pt) * 2017-08-23 2020-07-28 Csl Behring Gmbh método para a filtragem de virus do fator von willebrand
IL276971B2 (en) * 2018-02-28 2025-04-01 Plas Free Ltd In vitro device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
CN109078628B (zh) * 2018-08-27 2021-06-11 西北大学 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
KR20230074703A (ko) * 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
JP2024513983A (ja) 2021-04-13 2024-03-27 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 第ｖｉｉｉ因子または第ｖｉｉｉ因子／フォン・ヴィレブランド因子複合体を含む液体組成物
CN115181178B (zh) * 2021-09-04 2024-04-26 广东双林生物制药有限公司 一种从冷沉淀中制备人纤维蛋白原的方法
KR20240125667A (ko) 2021-12-30 2024-08-19 백스터 인터내셔널 인코포레이티드 피브린 실란트용 피브리노겐 및 트롬빈 용액 및 피브린 실란트 키트

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
EP0602173B1 (en) * 1991-09-05 1999-05-26 Baxter International Inc. Topical fibrinogen complex
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
DE69512416T3 (de) * 1994-07-14 2011-12-15 Croix Rouge De Belgique Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
CA2198928A1 (en) * 1994-09-02 1996-03-14 Samar Nath Roy Production and secretion of recombinant fibrinogen by yeast
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
AU6104799A (en) * 1998-09-24 2000-04-10 Ppl Therapeutics (Scotland) Limited Purification of fibrinogen from fluids by precipitation and hydrophoic chromatography
ES2327208T3 (es) 1999-12-23 2009-10-27 Csl Limited Separacion de fibrinogeno de proteasas de plasma.
AU5441101A (en) 1999-12-23 2001-07-03 Rodger H. Rast System and method for providing individualized dosing
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
EP1390485B1 (en) * 2001-05-21 2006-10-11 Omrix Biopharmaceuticals S.A. Removal of plasmin(ogen) from protein solutions
AUPR638801A0 (en) 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
CN1606447A (zh) * 2001-10-03 2005-04-13 克里斯托弗·J·伍尔弗顿 保存稳定的纤维蛋白原溶液
AU2002340776A1 (en) * 2001-10-30 2003-05-12 Novozymes A/S High throughput isolation of proteins by charge induction chromatography
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE10246125A1 (de) 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
ES2214967B1 (es) 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
DE102004009400A1 (de) * 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
CA2583081A1 (en) * 2004-06-16 2006-01-19 Bio-Rad Laboratories, Inc. Multichemistry fractionation
US20100062512A1 (en) * 2007-01-04 2010-03-11 Crucell Holland B.V. Purification of factor xi
WO2009007451A1 (en) 2007-07-11 2009-01-15 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
AU2009204998B2 (en) 2008-01-18 2014-03-27 F. Hoffmann-La Roche Ag Purification of non-glycosylated proteins
PL2300497T3 (pl) * 2008-06-24 2013-02-28 Octapharma Ag Sposób oczyszczania czynnika krzepnięcia VIII
ES2524886T3 (es) * 2010-01-08 2014-12-15 Profibrix Bv Preparados de fibrinógeno enriquecidos en fibrinógeno con una cadena alfa extendida
EP2619225B1 (en) * 2010-09-20 2016-06-15 Octapharma AG Process for production of fibrinogen
CN103429609A (zh) * 2010-12-08 2013-12-04 安姆根有限公司 在氨基酸存在下的离子交换层析
US10112972B2 (en) 2012-03-13 2018-10-30 Octapharma Ag Process for production of fibrinogen and fibrinogen produced thereby
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins

Also Published As

Publication number Publication date
CN104981476B (zh) 2018-10-09
AU2013354899B2 (en) 2018-05-17
JP6411360B2 (ja) 2018-10-24
AU2013203357A1 (en) 2014-06-19
KR102240978B1 (ko) 2021-04-19
EP3483173A1 (en) 2019-05-15
BR112015012854A2 (pt) 2017-07-11
CN109125714A (zh) 2019-01-04
EP2928905A4 (en) 2016-06-08
KR102403847B1 (ko) 2022-05-31
JP2019011346A (ja) 2019-01-24
RU2685956C2 (ru) 2019-04-23
CN109125714B (zh) 2022-08-02
KR20150090252A (ko) 2015-08-05
SG10201704484QA (en) 2017-07-28
BR112015012854B1 (pt) 2021-11-30
US11426680B2 (en) 2022-08-30
RU2015126551A (ru) 2017-01-10
SG11201504372UA (en) 2015-07-30
EP2928905B1 (en) 2018-11-21
US20170143805A1 (en) 2017-05-25
US20210283530A1 (en) 2021-09-16
WO2014085861A1 (en) 2014-06-12
JP6836562B2 (ja) 2021-03-03
KR20210042422A (ko) 2021-04-19
JP2016501878A (ja) 2016-01-21
US20150158906A1 (en) 2015-06-11
JP7774384B2 (ja) 2025-11-21
US9598461B2 (en) 2017-03-21
CA2893373A1 (en) 2014-06-12
AU2013203357B2 (en) 2015-08-27
CA3185085A1 (en) 2014-06-12
US20140154233A1 (en) 2014-06-05
JP2021073280A (ja) 2021-05-13
CN104981476A (zh) 2015-10-14
EP2928905A1 (en) 2015-10-14
US20190209948A1 (en) 2019-07-11
HK1214833A1 (en) 2016-08-05
AU2013354899A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
NL301178I2 (nl) Pegcetacoplan
EP4379102C0 (en) PATIENT INTERFACE
EP2830692A4 (en) Patient interface
CO7020866A2 (es) Péptidos terapéuticos
DK2854722T3 (da) Stomipose
BR302012002584S1 (pt) Configuracao aplicada em inalador
IL237914A0 (en) Benzamides
BR302012004766S1 (pt) Configuracao aplicada em injetor médico
DK2783256T3 (da) Terapeutiske briller
IL229081A0 (en) Isoxazolines as therapeutic agents
IL227732A0 (en) Cosmetic use
FR2993464B1 (fr) Pansement interface autoporte
CO6880064A2 (es) Métodos terapéuticos
HRP20190033T1 (hr) Pripravak
BR302012003979S1 (pt) Configuração aplicada em fármaco
ES1075603Y (es) Objeto terapeutico
FI20110263L (fi) Jaettava kahvakuula
UA22903S (uk) Масажер
UA22961S (uk) Масажер
BRDI7100220S (pt) Configuração aplicada em desensiladeira
BRDI7106280S (pt) Configuração aplicada em paliteiro
BR302012006072S1 (pt) Configuracao em conjunto de talheres
BR302012006074S1 (pt) Configuracao em conjunto de talheres
BR302012004499S1 (pt) Configuracao aplicada em mictório
BR302012004333S1 (pt) Configuracao aplicada em reômetro